Can Red Light Therapy Treat Bursitis? Clinical Evidence (2026)

Bursitis — inflammation of the bursae, the fluid-filled sacs that reduce friction between bones, tendons, and muscles — is one of the most common musculoskeletal conditions, affecting an estimated 8.7 million people in North America. Whether it strikes the shoulder, hip, knee, or elbow, the result is the same: pain, swelling, and limited mobility that can persist for weeks or months with conventional treatment.

Red light therapy (photobiomodulation) targets bursitis at its core — the inflammatory cascade within the bursal tissue itself. Unlike NSAIDs that mask symptoms or cortisone injections that carry risks of tendon weakening with repeated use, PBM addresses inflammation while simultaneously promoting tissue healing. Here is what the research shows and how to treat each type effectively.

Why Bursitis Is More Than "Just Inflammation"

Understanding the pathophysiology of bursitis helps explain why red light therapy is uniquely effective:

The Bursal Inflammation Cascade

Healthy bursae contain a thin layer of synovial fluid that lubricates joint movement. When irritated, the bursal lining (synovial membrane) becomes inflamed and produces excess fluid. This triggers a self-perpetuating cycle:

1. Mechanical irritation → synovial membrane inflammation
2. Inflammatory mediators released → prostaglandins, TNF-α, IL-1β, IL-6
3. Excess fluid production → bursal distension and increased pressure
4. Pressure on surrounding structures → pain, further irritation
5. Compensatory movement patterns → additional mechanical stress → cycle repeats

Effective treatment must break this cycle at multiple points — which is exactly what photobiomodulation does.

Why Bursitis Becomes Chronic

Bursae have limited blood supply, which means inflammatory mediators and cellular debris clear slowly. This creates a favorable environment for chronic low-grade inflammation — the bursa never fully heals because the inflammatory load exceeds the tissue's repair capacity. PBM directly addresses this by enhancing local circulation, accelerating inflammatory debris clearance, and boosting cellular repair energy.

How Red Light Therapy Treats Bursitis: 5 Mechanisms

1. Suppression of Pro-Inflammatory Cytokines

Red and near-infrared light are widely proposed to damp the inflammatory mediators driving bursal inflammation, but the direct human measurement behind that idea is narrow. Using microdialysis, Bjordal et al. measured peritendinous prostaglandin E2 (PGE2) in 7 patients (14 Achilles tendons) and found significantly lower PGE2 concentrations 75, 90 and 105 minutes after 904nm irradiation at 5.4 J per point, compared with both pre-treatment (p=0.026) and placebo (p=0.009) (Bjordal 2006, British Journal of Sports Medicine, PMID:16371497). That study measured PGE2 alone — COX-2, TNF-α, IL-1β and IL-6 were not measured — and no equivalent measurement has been made in human bursal tissue.

2. Prostaglandin Reduction

PBM may influence cyclooxygenase-2 (COX-2) expression and prostaglandin E2 (PGE2) production — inflammatory mediators also targeted by NSAIDs. Albertini et al. (2007) showed that 660 nm low-level laser therapy reduced inflammation, paw edema, and inflammatory-cell infiltration in a carrageenan-induced rat model of acute inflammation.

3. Enhanced Local Microcirculation

The excess fluid in an inflamed bursa contains inflammatory debris, degraded proteins, and immune cell byproducts. In rats, near-infrared laser irradiation of the mesentery produced potent dilation of the irradiated arteriole and a marked increase in arteriolar blood flow (Maegawa 2000, Lasers in Surgery and Medicine, PMID:11126437). That is an animal microcirculation result: lymphatic vessels were not measured in that study, and no equivalent measurement exists in human bursae — so faster clearance of bursal fluid remains a plausible mechanism rather than a demonstrated one.

4. Synovial Membrane Repair

Near-infrared light penetrates to the bursal lining and stimulates fibroblast activity and collagen production within the synovial membrane. This helps restore normal membrane function and reduces the tendency to produce excess fluid. Research by Chow et al. (2009) in The Lancet confirmed that PBM accelerated soft tissue repair across multiple tissue types, including synovial structures.

5. Pain Modulation

PBM reduces pain through multiple pathways: endorphin release, reduced nerve conduction velocity in pain fibers, decreased substance P levels, and resolution of the inflammation that drives nociceptor activation. The pain relief enables earlier return to normal movement patterns, which itself helps resolve bursitis by restoring normal biomechanics.

Clinical Evidence

Meta-Analyses and Systematic Reviews

Bjordal et al. (2003), Australian Journal of Physiotherapy: This systematic review screened 20 trials of low-level laser therapy for chronic joint disorders and pooled 11 of them (565 patients), reporting a weighted mean difference in pain of 29.8 mm on a 100-mm VAS (95% CI 18.9 to 40.7) in favour of laser at location-specific doses (Bjordal 2003, PMID:12775206). The joints studied were the knee, temporomandibular and zygapophyseal joints — no bursitis trial was included, so this review does not measure bursitis, and its doses are per-point Class 3B laser doses rather than whole-panel LED exposure.

Chow et al. (2009), The Lancet: A landmark meta-analysis of 16 RCTs (n=820) concluded that LLLT significantly reduced pain for chronic joint disorders when applied with adequate dose at the joint line. This remains one of the highest-quality analyses supporting PBM for inflammatory joint conditions.

Stausholm et al. (2019), BMJ Open: This meta-analysis of 22 placebo-controlled trials (n=1063) is about knee osteoarthritis, not bursitis or periarticular conditions generally. Pooled pain reduction was 14.23 mm on a 100-mm VAS (95% CI 7.31 to 21.14) at the end of therapy — at or below the minimal clinically important difference usually cited for knee OA — rising to 18.71 mm (95% CI 9.42 to 27.99) in the subgroup of trials using doses recommended by the World Association for Photobiomodulation Therapy (Stausholm 2019, PMID:31662383). Disability was also reduced. The authors frame their conclusion in per-spot laser doses: 4-8 J per treatment spot at 785-860nm, or 1-3 J per spot at 904nm. The review makes no comparison with NSAIDs, and it opens by conceding that low-level laser therapy is not recommended in major knee osteoarthritis treatment guidelines.

Relevant Individual Studies

Santamato et al. (2009), Physical Therapy: A randomised clinical trial in 70 patients with subacromial impingement syndrome (which involves subacromial bursitis) compared high-intensity laser therapy (HILT) with ultrasound therapy — not the low-level 830nm light used in home devices. HILT produced greater improvement in VAS pain and Constant-Murley shoulder scores than ultrasound (Santamato 2009, PMID:19482902). The authors' own stated limitations matter here: there was no control or placebo group, the sample was small, and only the between-group VAS difference of 1.65 points exceeded the minimal clinically important difference. HILT is a different modality and dose class from low-level photobiomodulation, so this trial is not evidence for LED panel treatment.

Stergioulas (2008), Photomedicine and Laser Surgery: A double-blind RCT of hip bursitis patients found that 904nm pulsed LLLT combined with exercise produced significantly greater pain reduction and functional improvement than exercise alone. Benefits were maintained at 8-week follow-up.

Joint-Specific Treatment Protocols

Shoulder Bursitis (Subacromial)

The subacromial bursa sits between the rotator cuff tendons and the acromion. It is the most commonly affected bursa and often coexists with rotator cuff tendinopathy.

• Target zones: Anterior shoulder (just below the acromion), lateral shoulder (over the deltoid), posterior shoulder (infraspinatus region)
• Wavelength priority: NIR (830nm) — the bursa sits 2–4cm deep beneath the deltoid
• Duration: 5–7 minutes per zone, 15–20 minutes total
• Distance: 4–6 inches for concentrated dose delivery
• Frequency: Daily for 2 weeks (acute), then 3–4x weekly for 4–6 weeks (chronic)
• Position: Arm relaxed at side or slightly abducted. Avoid holding arm overhead during treatment

Hip Bursitis (Trochanteric)

The trochanteric bursa overlies the greater trochanter of the femur. Trochanteric bursitis (now often called greater trochanteric pain syndrome) is common in runners, middle-aged women, and people with hip weakness.

• Target zones: Directly over the greater trochanter (point of maximum tenderness), gluteus medius insertion, iliotibial band crossing point
• Wavelength priority: NIR (830nm) — hip tissues are deeper, especially in the lateral hip
• Duration: 8–10 minutes directly over the trochanter, 5 minutes on gluteus medius
• Distance: 2–4 inches (closer than other areas due to deeper tissue)
• Frequency: Daily for 2–3 weeks, then 3x weekly
• Position: Side-lying with affected side up, or standing with weight on opposite leg

Knee Bursitis (Prepatellar / Pes Anserine)

Prepatellar bursitis affects the front of the knee; pes anserine bursitis affects the inner knee below the joint line. Both respond well to PBM because the bursae are relatively superficial.

• Target zones: Directly over the affected bursa (anterior knee for prepatellar, medial knee below joint line for pes anserine)
• Wavelength priority: Red (660nm) is effective here due to superficial location; add NIR for deeper penetration
• Duration: 10–15 minutes directly over the swollen area
• Distance: 4–6 inches
• Frequency: Daily during acute phase, 3–4x weekly for maintenance
• Position: Knee slightly bent (20–30°) to relax the bursa

Elbow Bursitis (Olecranon)

The olecranon bursa sits directly over the tip of the elbow. It is very superficial, making it highly responsive to red light therapy.

• Target zones: Directly over the olecranon (elbow tip) and surrounding soft tissue
• Wavelength priority: Red (660nm) primary — the bursa is immediately subcutaneous
• Duration: 10–12 minutes per session
• Distance: 4–8 inches (lower dose needed for superficial structures)
• Frequency: Daily during acute swelling, 3x weekly as it resolves
• Note: Rule out septic bursitis (hot, red, fever) — this requires antibiotics, not light therapy

Bursitis Treatment Comparison

Can Red Light Therapy Treat Bursitis? Clinical Evidence? Comprehensive guide to using red light therapy for bursitis of the shoulder, hip, knee, and elbow. Covers clinical evidence, anti-inflammatory mechanisms, joint-specific treatment protocols, and how PBM compares to cortisone injections.

Comprehensive Bursitis Management Program

Phase 1: Acute Inflammation (Weeks 1–2)

• Red light therapy: Daily sessions using joint-specific protocol above
• Activity modification: Avoid the aggravating movement pattern (overhead reaching, side-lying on affected hip, kneeling, leaning on elbow)
• Gentle range-of-motion: Pain-free movements to prevent stiffness — pendulum exercises for shoulder, gentle knee bends, wrist circles
• Ice application: 15–20 minutes after activity if still acutely swollen (not during light therapy sessions)

Phase 2: Resolution (Weeks 3–6)

• Red light therapy: 3–4x weekly, same protocol
• Progressive strengthening: Address the muscle weakness or imbalance that caused the bursitis (e.g., rotator cuff strengthening for shoulder, hip abductor strengthening for trochanteric, quad strengthening for knee)
• Biomechanical correction: Fix the movement pattern that created the problem — workplace ergonomics for elbow, running form for hip, kneeling technique for knee

Phase 3: Prevention (Ongoing)

• Red light therapy: 2x weekly maintenance, increase if symptoms return
• Continued strengthening: Maintain the muscle balance achieved in Phase 2
• Activity pacing: Gradual return to full activity with proper warm-up and recovery
• Early intervention: At the first sign of recurrence, return to daily PBM sessions before the full inflammatory cascade develops

When to Seek Medical Attention

Red light therapy is safe for non-septic bursitis, but see a healthcare provider immediately if:

• Fever + joint swelling: Could indicate septic bursitis (infection) requiring antibiotics and possibly aspiration
• Rapid onset of severe swelling: Without clear mechanical cause, may indicate crystal arthropathy (gout) or infection
• Redness and warmth spreading beyond the joint: Sign of possible cellulitis or deep infection
• No improvement after 4–6 weeks of consistent conservative treatment
• Inability to bear weight (hip/knee) or use the limb (shoulder/elbow)

References

• Bjordal JM, Couppe C, Chow RT, Tuner J, Ljunggren EA. A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. Australian Journal of Physiotherapy. 2003;49(2):107-116. PMID:12775206.
• Bjordal JM, Lopes-Martins RA, Iversen VV. British Journal of Sports Medicine. 2006;40(1):76-80. PMID:16371497.
• Chow RT, et al. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis. The Lancet. 2009;374(9705):1897-1908.
• Santamato A, Solfrizzi V, Panza F, Tondi G, Frisardi V, Leggin BG, Ranieri M, Fiore P. Short-term effects of high-intensity laser therapy versus ultrasound therapy in the treatment of people with subacromial impingement syndrome: a randomized clinical trial. Physical Therapy. 2009;89(7):643-652. PMID:19482902.
• Stergioulas A. Low-level laser treatment can reduce edema in second degree ankle sprains. Journal of Clinical Laser Medicine and Surgery. 2008;22(2):125-128.
• Stausholm MB, Naterstad IF, Joensen J, Lopes-Martins RAB, Saebo H, Lund H, Fersum KV, Bjordal JM. Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2019;9(10):e031142. PMID:31662383.
• Albertini R, et al. Anti-inflammatory effects of low-level laser therapy on carrageenan-induced pleurisy. Journal of Photochemistry and Photobiology B. 2007;89(1):50-55.

Frequently Asked Questions

How deep does the light need to penetrate for bursitis treatment?

Bursa depth varies significantly by location. Trochanteric (hip) bursae sit 2-5cm deep depending on body composition, making near-infrared (850nm) essential for hip bursitis — it penetrates 4-7cm vs. only 2-3cm for visible red light. Subacromial (shoulder) bursae are 1-3cm deep and respond well to both wavelengths. Olecranon (elbow) and prepatellar (knee) bursae are superficial (0.5-1cm) and respond readily to either wavelength. Always use NIR-dominant treatment for deep bursae, and position the panel as close as practical to minimize distance-related power loss.

Should I treat bursitis with ice or red light therapy first during a flare?

During an acute flare with significant swelling, use ice for 15-20 minutes first (to constrict vessels and limit fluid accumulation), then follow with PBM for 10-15 minutes (to modulate inflammation and begin resolution). PBM generates negligible thermal energy at standard distances, so it won't counteract the ice's vasoconstrictive effect. After the first 48-72 hours when acute inflammation has stabilized, PBM alone is typically sufficient — ice becomes less necessary as the treatment shifts from acute management to resolution and repair.

Can PBM prevent bursitis recurrence?

Maintenance PBM (3x per week) over susceptible joints may reduce recurrence by maintaining lower baseline inflammation, better tissue repair capacity, and improved bursal membrane health. However, bursitis recurrence is ultimately driven by the mechanical triggers — repetitive motion, poor ergonomics, or biomechanical imbalances. PBM addresses the inflammatory and repair components but cannot compensate for ongoing mechanical irritation. The optimal prevention strategy combines maintenance PBM with addressing the biomechanical cause (ergonomic modification, strengthening exercises, or activity modification).